Horizon Discovery enters agreement with provider of molecular diagnostic testing solutions
Horizon Discovery Group plc, the world-leader in the application of gene editing technologies, today announces it has entered into an agreement with a global leader in the development and provision of innovative molecular diagnostic testing solutions (the Client).
Horizon Discovery partners with Amplycell SA for bioproduction cell line optimisation
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, including the provision of bioproduction cell lines, today announced it has entered into a research and development collaboration, and licence agreement with AmplyCell SA, to evaluate the impact of AmplyCell’s BOOST cell line optimisation technology on Horizon’s parental GS (glutamine synthetase) null…
Horizon Discovery launches Multiplex I cfDNA Reference Standard set in Synthetic Plasma
Horizon Discovery Group plc, the world leader in the application of gene editing technologies including molecular reference standards, today announces the launch of its first HDx™ cfDNA (cell-free DNA) Reference Standard in Synthetic Plasma.
Horizon Discovery signs a Master Service Agreement with a top three pharmaceutical company
Horizon Discovery today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company extending support for their drug discovery and development efforts to Horizon’s full suite of services.
Horizon Discovery Group 'on track to meet market expectations'
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces a trading update ahead of its full year results for the 12 months ended 31 December 2016. The Group intends to announce its preliminary full year 2016 results in May 2017.
Horizon broadens gene editing capabilities: CRISPR license extension & grant-funded research
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces that it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR edited cell lines for the Good Manufacturing Practice (GMP) manufacturing of biotherapeutics.
International Trade Minister Greg Hands visits fast-growing Cambridge life sciences company
Horizon Discovery Group, world leader in the application of gene editing technologies, last week hosted International Trade Minister Greg Hands at its facility in Cambridge.
Horizon Discovery provides progress update on its cell line catalogue business
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today provides an update on the commercial operation of its catalogue cell line business through the offering of Cell Bank subscriptions, which have generated over £0.7m in revenue since launch in Q3 2016.
Horizon Discovery provides a progress update on its biomanufacturing business
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today provides an update on the commercial operation of its Biomanufacturing business with significant growth in cell line licensing revenue to over £1.3m already recognised in 2016, a more than three times increase over 2015.
Horizon Discovery product included in The Scientist ‘Top 10 Innovations’ list for fourth year
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announced leading industry publication The Scientist has included one of its portfolio products in its ‘Top 10 Innovations’ list for the fourth year in a row.
Horizon Discovery partners with Sophia Genetics on NGS Reference Standards for oncology
Switzerland- based Sophia Genetics, the global leader in Data-Driven Medicine, and Horizon Discovery Group plc, the world-leader in the application of gene editing technologies, today announced they have entered into a new partnership to improve the quality of Next Generation Sequencing (NGS) based genetic testing in oncology patient samples.
Horizon Discovery enters Chinese clinical diagnostics market
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces that it has entered into partnerships with three leading Chinese diagnostic kit developers. Under the terms of the agreements, Horizon will provide HDx Reference Standards for novel Next Generation Sequencing (NGS) assay development, clinical trials, and ultimately for inclusion as in…
Horizon Discovery and CareDx enter into OEM agreement to develop transplant testing
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces it has entered into an Original Equipment Manufacturer (OEM) agreement with CareDx®, Inc., a molecular diagnostics company focused on the discovery, development and commercialisation of clinically differentiated, high-value, diagnostic surveillance solutions for transplant patients.
Horizon Discovery: progress update on its high-throughput molecular screening platform
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today provides an update on the operation of its high-throughput molecular screening platform, which includes drug combination and immuno-oncology screening. Horizon announces the signing of more than £800,000 of new drug combination and immuno-oncology service agreements with revenue to be recognised…
Horizon Discovery signs licensing agreement for biomanufacturing cell lines
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces a new licensing agreement with an unnamed commercial partner for access to Horizon bioproduction cell lines. The subscription deal, a first of its kind for Horizon, is valued at a minimum of £500,000.
Horizon Discovery Group and Ventana Medical Systems sign agreement for reference standards
The Agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards in cancer tissue diagnostics to support the development and validation of IHC assays.
Horizon Discovery Group plc signs three diagnostic agreements worth an initial $3.3 million
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, today announced it has signed development agreements with three major developers of companion diagnostic tests worth an initial c$3.3 million (c£2.2 million).
Horizon Discovery Group plc and Axol Bioscience Ltd announce strategic partnership
Horizon Discovery Group plc, the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, and Axol Bioscience Ltd (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems, announce they have formed a strategic…
Horizon Discovery Group plc launches new e-commerce platform and expands UK headquarters
Horizon Discovery Group plc, the international life science company supplying genomics research tools and services that power genomic research and the development of personalised medicines, today announces the launch of its new e-commerce platform and integrated web-shop, and the expansion of its UK-based headquarters.
Horizon Discovery Group in-licenses oncology programme from Servier
Horizon Discovery Group plc announces today that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company. The agreement is potentially worth over £50 million to Horizon in preclinical and clinical milestones, payments linked to net sales, and tiered royalties on future product sales.
Horizon Discovery Group plc and Abcam plc sign license and supply agreement
Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company”), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, and Abcam plc (AIM: ABC), a global leader in the supply of research antibodies, today announced the formation of a license and supply agreement between the two companies.
Horizon Discovery Group plc and Redx Pharma plc sign cancer research collaboration
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, and Redx Pharma plc, today announce a research collaboration to progress Redx’s novel pan-RAF inhibitor program, for out-licensing in oncology indications including colorectal cancer, the fourth most common cancer and…
Horizon to invest up to £10m leveraged funding in molecular cancer therapeutics
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, today announces that, further to the trading update announced on 20th July 2015 and as anticipated in the recently announced £25 million share placement, it will invest up to £10 million in its leveraged R&D…
Horizon Discovery Group plc publishes trading update
Horizon Discovery Group plc, the international life science group supplying research tools and services that power genomics research and the development of personalised medicines, today announces a trading update for the six months ended 30 June 2015, ahead of its interim results on 22 September 2015.
Horizon and DefiniGEN collaborate to develop gene-engineered iPS-based cell lines
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, and DefiniGEN Ltd, a leading provider of stem cell products and services, today announced their collaboration to develop a range of unique, gene-engineered iPS (induced pluripotent stem)-based cell lines for use in…